The secondary outcome measures of the trial
| Secondary clinical outcome measures at 1 year | Further laser (control group) (n = 18) | PPV (intervention group) (n = 15) |
|---|---|---|
| *IQR, interquartile range. | ||
| Number (%) patients improving by 0.3 logMAR compared with baseline | 2 (11%) | 1 (6%) |
| Number (%) patients with a 30% or greater reduction in OCT central macular thickness | 6 (33%) | 7 (47%) |
| Number of patients demonstrating treatment failure 6 months after intervention | 8 | 5 |
| Median central nuclear density [IQR*] | 35.48 [30.35, 38.45] | 45.01 [31.85, 58.65] |
| No (%) of patients developing complications | 0 | 1 |